| Literature DB >> 33356327 |
Lirui Wang1, Chunlei Zhang1, Yuping Hong1, Xinhong Li2, Tangan Li1, Ang Gao1, Shaojun Pan3, Bin Liu1, Han Jin1, Daxiang Cui1,4.
Abstract
Epigenetic dysregulations resulting from the defects of epigenetic regulators are often reversible in tumorigenesis, making them promising cancer therapeutic targets. However, the limited specificity of action, short-term stability, and low retention of the epigenetic drugs greatly impede their clinical efficacy against solid tumors. Herein a method of combinatorial delivery of epigenetic modulatory drugs via a molecular self-assembly strategy was developed using inhibitors of DNA methyltransferases and histone deacetylases. The drug-drug conjugates can self-assemble into nanofibers with enhanced chemical stability. The nanofibers synergistically regulate aberrant DNA methylation and histone deacetylation, subsequently reprogram the gene expression profiles, and finally inhibit gastric cancer cell proliferation and promote cell apoptosis. The superior in vivo therapeutic efficacy of the nanofibers could be ascribed to the prolonged retention and accumulation in tumors and the minimized off-target effects. Therefore, this design of epigenetic-drug-based nanofiber formulation may provide a valuable paradigm for cancer therapy through epigenetic reprogramming.Entities:
Keywords: Cancer therapy; DNA methylation; Epigenetic modulators; Histone deacetylation; Nanofibers
Mesh:
Substances:
Year: 2020 PMID: 33356327 DOI: 10.1021/acs.nanolett.0c03665
Source DB: PubMed Journal: Nano Lett ISSN: 1530-6984 Impact factor: 11.189